Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.…
Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer
Cardiff Oncology (NASDAQ: CRDF) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 30 employees.
The shares were at 0.8528 USD on 20 November 2026, down 61.1% over 52 weeks. Its 52-week range is 0.7107 USD to 3.310 USD: the price is 74.2% below the high and 20.0% above the low.
Its market capitalisation is 66.34M USD.
Cardiff Oncology reports return on equity of -101.0% and revenue down 14.1% year over year.
It holds more cash than debt, a net cash position of 34.06M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 2 March 2027.